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The prognosis of patients diagnosed as having hypertrophic
cardiomyopathy at advanced age has not been well defined.
This study details follow-up information obtained for 95
patients initially diagnosed as having hypertrophic cardio-
myopathy at age ~65 years. Seventy-five percent of patients
were symptomatic, as defined by the presence of chest pain,
dyspnea or syncope, and the mean ventricular septal thick-
ness was 20 mm. The median duration of follow-up study
was 4.2 years. The survival rate at 1and 5 years was 95%
and 76%, respectively, which was not significantly different
from that of an age- and gender-matched control group. Of
patients presenting with New York Heart Association func-
tional class I or II dyspnea, only 18% progressed to class III
Although originally considered a disease primarily of young
adults, hypertrophic cardiomyopathy is commonly diag-
nosed in older patients (1). Whiting et al. (2) reported that
32% of patients presenting with hypertrophic cardiomyopa-
thy were >60 years of age. In a community hospital-based
series of patients with hypertrophic cardiomyopathy re-
ported by Petrin and Tavel (3), 83% of patients were >50
years of age. Likewise, in a recent study from the Cleveland
Clinic (4), hypertrophic cardiomyopathy was more com-
monly diagnosed in patients ~65 years of age than in those
<40 years of age. Older individuals with hypertrophic car-
diomyopathy present with symptoms similar to those of
younger patients, such as dyspnea, chest pain and syncope
(5). However, the significant differences observed in the
cardiac morphology of elderly and young hypertrophic
hearts emphasize the heterogeneity of this disease and
suggest that the development of hypertrophic cardiomyopa-
thy in different age groups may be the result of different
pathologic processes (4,6-9).
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or IV during the follow-up period. However, patients
presenting with class III dyspnea had a 1 year mortality
rate of 36%, significantly higher than that of control
subjects (p < 0.0(3). Of the echocardiographic variables,
indexed left atrial size was most strongly associated with
reduced survival (p < 0.0(8).
These results suggest that the prognosis of elderly
patients with hypertrophic cardiomyopathy is generally
favorable. Certain clinical and echocardiographic variables
appear to be of use in identifying patients with a less
favorable prognosis.
(J Am Coil CardioI1990;16:821-6)
Whether the structural differences observed among dif-
ferent age groups with hypertrophic cardiomyopathy corre-
late with differences in prognosis is unclear. There is rela-
tively little information concerning the natural history of
hypertrophic cardiomyopathy in the elderly. For example,
one of the largest follow-up studies (10) involving 254
patients contained only 7individuals >60 years of age. Other
studies 01,12) that suggested that hypertrophic cardiomy-
opathy has a benign course in older individuals contained
few patients >65 years of age. Therefore, to better define the
prognosis of this disorder in elderly patients, we studied the
clinical characteristics and course of 95 patients initially
diagnosed with hypertrophic cardiomyopathy at age ~65
years and compared their survival with an age- and gender-
matched control group.
Methods
Patient selection. Of the 530 patients diagnosed with
hypertrophic cardiomyopathy by two-dimensional echocar-
diography at our institution between 1978 and 1985, 134
(25%) were ~65 years of age. The history of these patients
was retrospectively reviewed. Patients whose original diag-
nosis of hypertrophic cardiomyopathy had been made before
65 years of age (n = 24), who had undergone prior cardiac
surgery (n = 7) or whose death was considered imminent
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because of associated illnesses (n = 8) such as untreatable
malignancy were excluded, resulting in a study group of 95
patients. All patients demonstrated typical clinical manifes-
tations of hypertrophic cardiomyopathy as determined by
history, physical examination and echocardiography. Pa-
tients with a history of hypertension were included in the
study. In the vast majority of cases, the hypertension was
mild or well controlled with therapy and was clearly dispro-
portionate to the degree of left ventricular hypertrophy
observed by echocardiography.
Echocardiographic diagnosis. The two-dimensional echo-
cardiogram of each patient was reviewed by two experienced
echocardiographers to confirm the presence of standard echo-
cardiographic criteria to establish the diagnosis of hypertrophic
cardiomyopathy. Specifically, the diagnosis required the pres-
ence ofa hypertrophied (ventricular septal thickness 2:: 15 mm),
nondilated left ventricle with normal or hyperdynamic left
ventricular systolic function (13). Supportive but not necessary
diagnostic criteria included either rest or provocable systolic
anterior motion of the mitral valve (14) and the demonstration
of a left ventricular outflow tract pressure gradient by Doppler
echocardiography (either at rest or after provocation) as evi-
denced by a late-peaking left ventricular outflow tract flow
velocity of 2:: 1.6 mls. The presence of localized basal septal
hypertrophy was not considered to represent hypertrophic
cardiomyopathy unless accompanied by systolic anterior mo-
tion of the mitral valve and a demonstrable left ventricular
outflow tract pressure gradient (15).
Clinical data. The following clinical data were recorded
for each patient: I) New York Heart Association functional
class (16), 2) history of chest pain or syncope, 3) history of
hypertension, 4) presence of coronary artery disease, 5)
nature and severity of concomitant diseases, 6) medications,
7) blood pressure, 8) body surface area, 9) presence of a
heart murmur and response to Valsalva maneuver, 10)
electrocardiographic (ECG) abnormalities, and II) results of
cardiac catheterization (if performed).
Echocardiographic data. The following echocardio-
graphic measurements were recorded for each patient: I)
diastolic ventricular septal and free wall thickness, 2) left
ventricular cavity dimensions during systole and diastole, 3)
left atrial size, and 4) presence or absence of systolic anterior
motion of the mitral valve or mitral annular calcification. In
addition, the pattern of left ventricular hypertrophy was
noted for each patient and assigned to one of the following
categories: I) concentric, 2) asymmetric septal, 3) basal
septal, or 4) apical. In patients who underwent Doppler
echocardiographic examination, the left ventricular outflow
tract flow velocity was recorded.
Follow-up. The beginning of the follow-up period was
defined as the date that the echocardiogram identifying the
patient with hypertrophic cardiomyopathy at our institution
was performed. Follow-up information was available for all
patients and was obtained from review of records of repeat
examinations at the Mayo Clinic, patients' responses to a
mailed questionnaire or telephone call and information sup-
plied by relatives or death certificates. In all but three cases,
the cause of death could definitely be classified as either
cardiac or noncardiac. However, in patients with cardiac
death, it was not always clear if death was sudden, nor could
it always be determined whether sudden death was the result
of primary arrhythmia or myocardial infarction. Therefore, a
subclassification of cardiac death was not made.
Statistical methods. Probabilities of survival and survival
free from cardiac death were estimated by use of the
Kaplan-Meier method (17). Expected survival was calcu-
lated by using a hypothetical age- and gender-matched
cohort of patients derived from the 1980 United States West
North Central Life Tables (18). Survival curves were com-
pared by using the log-rank test (19). The associations of
continuous and multiple variables with survival were esti-
mated by using the log-rank test or the Cox proportional
hazards model (20). Variables that were significant (p < 0.05)
on univariate analysis were included in a multivariate anal-
ysis. Data are presented as mean values ±: I standard error.
The analysis of survival free from cardiac death was
performed twice-first by excluding the three patients whose
cause of death could not be determined and then by includ-
ing them as cardiac deaths. The conclusions of each analysis
were the same. To provide a "worst case" scenario, the
analyses of cardiac death reported included these three
deaths as cardiac deaths.
Results
Patient characteristics (Table 1). The study group con-
sisted of 95 patients (39% men and 61 % women). The mean
age was 71.8 ±: 5.1 years (range 65 to 90). Seventy-five
percent of patients were symptomatic as defined by the
presence of chest pain, dyspnea or syncope. Although 48%
of patients had a history of hypertension, the mean blood
pressure of the study group was 146 ±: 26 mm Hg systolic
and 80 ±: II mm Hg diastolic.
The initial diagnosis ofhypertrophic cardiomyopathy was
made at our institution in 79% of patients. Seventeen
percent of patients had a history of definite or suspected
myocardial infarction; 16% had associated medical illnesses,
including diabetes mellitus, chronic obstructive pulmonary
disease, pulmonary fibrosis, malignancy and peripheral ath-
erosclerotic vascular disease. At the time of presentation to
our institution, 28% of patients were taking a beta-adrenergic
blocking medication and 6% were taking a calcium channel
antagonist.
Echocardiographic data (Table 2). Two-dimensional
echocardiography was performed in all patients and Doppler
studies were obtained in 29%. The mean ventricular septal
diastolic thickness was 20 ±: 4 mm (normal ~I2 mm).
Systolic anterior motion of the mitral valve was present in
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Table 1. Clinical Characteristics of 95 Patients at Presentation
Figure 1. Overall survival of 95 elderly patients with hypertrophic
cardiomyopathy and expected survival of an age- and gender-
matched control group. No significant difference (p = 0.28) in
survival was noted. Numbers in parentheses represent the number
of patients at each follow-up period.
Patients
Mean age (yr)
Male
Female
Hypertension
Symptoms
Chest pain
Syncope
NYHA functional class dyspnea
I
II
III
IV
Asymptomatic
Blood pressure (mm Hg)
Systolic
Diastolic
Systolic murmur
Left ventricular hypertrophy on ECG
No.
95
71.8±5.1
37 (39)
58 (61)
46 (48)
47 (49)
16 (17)
51 (54)
32 (34)
12 (13)
0(0)
24 (25)
146 ± 26
80 ± 11
92 (97)
56 (60)
100 (87) (74)
(62)
(51)
80
';:?0
i6
60
>.~
40~en
20 - Expected
- Observed
0
0 2 3 4
Years
(34)
5 6
Table 2. Echocardiographic Data in 95 Patients
Values in parentheses are percent of total. ECG = electrocardiogram:
NYHA = New York Heart Association.
82% of patients and mitral annular calcification was ob-
served in 36%. The two most common patterns of left
ventricular hypertrophy were asymmetric septal (75%) and
concentric (21 %). Three patients had basal septal hypertro-
phy and one patient had apical hypertrophic cardiomyopa-
thy. A left ventricular outflow tract gradient (mean maximal
instantaneous gradient 47 ± 38 mm Hg) was present in 75%
of patients who underwent Doppler echocardiography.
Angiographic data. Eighteen patients (19%) underwent
cardiac catheterization; a left ventricular outflow tract gra-
Mean ventricular septal diastolic thickness (mm)
Mean left ventricular free wall thickness (mm)
Mean left ventricular cavity dimension (mm)
Diastole
Systole
Mean fractional shortening (%)
Mean left atrial size (mm)
Systolic anterior motion of mitral valve
Mitral annular calcification
Pattern of left ventricular hypertrophy
Concentric
Asymmetric septal
Basal septal
Apical
Doppler study performed
Left ventricular outflow tract gradient present
Mean maximal instantaneous gradient (mm Hg)
Values in parentheses represent percent of total.
Value
20 ± 4
14 ± 3
41 ± 6
21 ± 5
48
42 ± 8
78 (82)
34 (36)
20 (21)
71 (75)
3 (3)
1(1)
27 (29)
20
47 ± 38
dient (mean peak to peak gradient 62 ± 47 mm Hg) was
observed in 13. Significant coronary artery disease defined
by the presence of at least one coronary stenosis 270% was
present in six patients.
Follow-up data. Patients were followed up for a median
of 4.2 years (range 6 days to 9.1 years). At least 1 year of
follow-up data were obtained for 92% of patients. The mean
New York Heart Association functional class of patients at
presentation was 1.6 (Table I). Among patients presenting
with functional class I or II dyspnea, 18% progressed to class
III or IV during the follow-up period. The mean functional
class of the 71 survivors at final follow-up study was 2. There
were 24 deaths-II cardiac, 10 noncardiac and 3of unknown
cause. Medical therapy during follow-up included a beta-
blocker or calcium channel antagonist, or both, in 74% of
patients. One patient underwent septal myectomy-myotomy
and coronary artery bypass grafting 5 days after the estab-
lishment of the diagnosis of hypertrophic cardiomyopathy at
our institution; this patient died on postoperative day I.
Survival in the study group was compared with that ofan
age- and gender-matched control group. There was no
significant difference in observed and expected survival rates
at 5 years offollow-up (p = 0.28; Fig. 1). Survival of patients
at 1 and 5 years was 95% and 76%, respectively, compared
with 97% and 82%, respectively, for control subjects.
Several clinical and echocardiographic variables were
examined for an association with reduced survival during
the follow-up period. Univariate analysis revealed that nei-
ther gender, history of hypertension, pattern of left ventric-
ular hypertrophy nor presence of systolic anterior motion of
the mitral valve was associated with decreased survival.
There was no significant difference in survival between
patients taking a beta-blocker or a calcium channel antago-
nist, or both, and patients not taking these medications.
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Figure 3. Survival free of cardiac death of 95 elderly patients with
hypertrophic cardiomyopathy. Format as in Figure I.
Figure 2. Survival of 95 elderly patients with hypertrophic cardio-
myopathy by New York Heart Association functional class dyspnea
at presentation. Format as in Figure I.
Advanced functional class dyspnea was associated with
reduced survival (p < 0.(03). Patients presenting with class
III symptoms (n = 12) had a I year survival rate of 64%
compared with 98% and 100% for patients with class I and II
dyspnea, respectively (Fig. 2). Among the echocardio-
graphic variables, only indexed left atrial size (p < 0.(08)
and indexed ventricular septal thickness (p < 0.(01) were
associated with reduced survival. Multivariate analysis re-
vealed that only indexed left atrial size was independently
associated with decreased survival (p < 0.05).
The incidence ofcardiac death was approximately 3% per
year (Fig. 3). Advanced functional class dyspnea (p <
0.002), increased indexed left atrial size (p < 0.004) and
increased indexed ventricular septal thickness (p < 0.003)
were each associated with an increased incidence of cardiac
death. On multivariate analysis. advanced dyspnea (p <
0.05) and indexed left atrial size (p < 0.05) were indepen-
dently associated with cardiac death (Fig. 4).
Figure 4. Relation of left atrial size to cardiac mortality in 94
patients. Patients were divided into terciles on the basis of indexed
left atrial size. Lower tercile = indexed left atrial size <22 mm/m2
(n = 31): mid tercile = indexed left atrial size between 22 and 26
mm/m2 (n = 31): upper tercile = indexed left atrial size >26 mm/m2
(n =32). Survival free of cardiac death is shown for each tercile. On
multivariate analysis. indexed left atrial size was independently
associated with cardiac death (p < 0.05l. Format as in Figure I.
Discussion
Hypertrophic cardiomyopathy in advanced age. Our re-
sults indicate that patients presenting with hypertrophic
cardiomyopathy at advanced age generally do well, with a
survival rate no different from that of an age- and gender-
matched control group. The annual cardiac mortality rate
was 3%, which, considering the mean age of study group
(71.8 years), is relatively low. We did not subclassify cardiac
deaths (that is, sudden versus nonsudden) because this could
not always be determined with certainty, even after review
of the death certificate or correspondence with relatives. In
addition, sudden death in this age group cannot necessarily
be attributed to hypertrophic cardiomyopathy because of the
increased incidence of coronary artery disease with ad-
vanced age. To our knowledge, this is the only series dealing
with the natural history of hypertrophic cardiomyopathy that
compares the survival of the study group with that of a
control group without the disease, an aspect that is of
considerable importance when studying the impact on sur-
vival of a disease process in a group of elderly patients. The
clinical and echocardiographic findings in the study group
(Tables I and 2) are quite similar to those reported in other
series (1,4,21) dealing with the initial presentation of elderly
patients with hypertrophic cardiomyopathy.
Reasons for differences in outcome between elderly and
younger patients. Although our patients tended to do well,
previous natural history studies (9,22) have emphasized the
relatively poor prognosis of those with hypertrophic cardio-
myopathy. There are several possible explanations for the
apparent difference in outcome between elderly and younger
patients. First, elderly individuals with hypertrophic cardio-
6543
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myopathy may represent a subgroup of patients with a
benign form of this disorder. one that begins during or before
middle age, yet is compatible with long life. Although we
included only patients originally diagnosed with hyper-
trophic cardiomyopathy at age ~65 years, congestive heart
failure (22%), a cardiac murmur (60%) or an abnormal ECG
(37%) had been present in a significant number of patients
before the diagnosis of hypertrophic cardiomyopathy was
established. It is likely that many of these patients had had
hypertrophic cardiomyopathy for many years and therefore
it is not surprising that they continued to do well. Likewise.
patients with more severe forms of hypertrophic cardiomy-
opathy would be expected to die at an earlier age and thus be
excluded from the elderly group in this study.
Second, because idiopathic hypertrophy in older individ-
uals may be the result ofdifferent pathologic processes from
those active in younger patients, the result might be a more
benign clinical course. Although our study did not address
this issue, the morphologic differences observed between
elderly and young hypertrophic hearts suggest that different
disease processes may be involved. Lever et al. (4) noted the
presence of an ovoid cavity contour and normal septal
curvature in elderly patients with hypertrophic cardiomyop-
athy in contrast to the crescent-shaped left ventricular cavity
and reversed septal curvature in younger persons. Lewis and
Maron (7) suggested that the mechanism of dynamic left
ventricular outflow tract obstruction may differ between
younger and older patients, with obstruction in the latter
group being caused by anterior displacement of the mitral
valve as a result of mitral annular calcification. as well as
systolic posterior excursion of the ventricular septum. In
addition, necropsy studies of normal hearts by Kitzman et
al. (23) showed that ventricular septal thickness increases
with age and that the mean septal to left ventricular free wall
ratio exceeds 1.2 beyond the 7th decade of life. Thus, the
development of hypertrophic cardiomyopathy in elderly
patients may be contributed to by "benign" processes
associated with aging. as opposed to more "malignant"
processes that may be responsible for the development of
idiopathic hypertrophy in younger patients.
Third, referral bias may aCCOl/nt for the apparent differ-
ence in prognosis between older and younger patients with
hypertrophic cardiomyopathy. As pointed out by Spirito et
al. (24), the clear majority of reports concerning the adverse
prognosis of hypertrophic cardiomyopathy have originated
from a small number of tertiary care institutions that are
recognized for their interest and expertise in this disease.
Patients in these studies have tended to be young and to have
relatively severe symptoms. Spirito et al. (24) also proposed
that the prognosis of hypertrophic cardiomyopathy may be
more benign than originally suggested. The mean age of
patients in their study was 44 years. Hence, the prognosis of
the majority of patients with hypertrophic cardiomyopathy,
regardless of age, may be relatively benign. However. our
study is also not free of referral bias. Patients were selected
from an echocardiographic registry. Because older individ-
uals presenting with severe chest pain and dyspnea may
have had the diagnosis of hypertrophic cardiomyopathy
established at cardiac catheterization without referral to the
echocardiographic laboratory. patients with a potentially
poorer prognosis may have been excluded from our study.
Nevertheless, the most common clinical scenario leading to
the diagnosis of hypertrophic cardiomyopathy is that of the
patient who is referred to the echocardiographic laboratory
for the evaluation of a cardiac murmur, and our results are
relevant to such patients.
Factors associated with adverse prognosis. A benign clin-
ical course was not a universal feature of the study group.
Patients presenting with functional class I or II dyspnea had
a survival rate no different from that of control subjects and
only 18% progressed to functional class III or IV during the
follow-up period. However, patients presenting with class
III dyspnea had a I year mortality rate of 36%. which was
significantly higher than that of control subjects. These
results are in accordance with those of Lewis and Maron (7),
who followed up the clinical course of 52 severely sympto-
matic (50 of 52 patients in either functional class III or IV)
elderly patients with hypertrophic cardiomyopathy and
found a high incidence of symptom progression and need for
surgical management (myectomy-myotomy). Likewise,
McKenna et al. (10) reported that severe dyspnea is predic-
tive of death in younger patients with hypertrophic cardio-
myopathy. Of the two-dimensional echocardiographic vari-
ables examined, indexed left atrial size had the strongest
association with subsequent death. It does not appear that
this association is the result of coexisting hypertension
because a history of hypertension was not predictive of
subsequent death and the association of indexed left atrial
size with decreased overall and cardiac survival was inde-
pendent of systolic blood pressure in the multivariate anal-
ySIS.
Therapy and clinical course. We found no difference in
either overall or cardiac survival between patients taking
either a beta-blocker or a calcium channel antagonist and
patients not taking these medications. These results are
similar to those reported for younger groups of patients
(22.25). It must be emphasized. however, that the patients in
this study were retrospectively identified and that the selec-
tion of therapy was subject to clinical bias. It would be
incorrect to conclude from our results that medical therapy
is of no benefit in elderly patients with hypertrophic cardio-
myopathy because the study was not designed to adequately
address this issue.
Hypertension and hypertrophic cardiomyopathy. As with
other studies (2,3.7) dealing with hypertrophic cardiomyop-
athy in the elderly, we included pattents with a history of
hypertension, provided that their clinical and echocardio-
graphic presentation was typical of the disease. Patients with
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or without a history of hypertension did not differ signifi-
cantly with regard to clinical presentation, pattern of left
ventricular hypertrophy or survival. These results are con-
sistent with those of Karam et al. (26), who showed that,
with the exception of increased posterior wall thickness,
hypertensive patients with hypertrophic cardiomyopathy do
not differ echocardiographically from normotensive patients
with this disease. It appears, therefore, that hypertension is
not the primary cause of hypertrophic cardiomyopathy in
these patients. Thus, the entity of mild to moderate hyper-
tension with disproportionately severe concentric or asym-
metric left ventricular hypertrophy can be included within
the spectrum of hypertrophic cardiomyopathy (8,27).
Conclusions. This study of 95 patients ::::65 years of age
with echocardiographically diagnosed hypertrophic cardio-
myopathy provides new information regarding the natural
history of the disease in the elderly and is unique in that
survival is compared with that in an age- and gender-
matched control group. Natural history studies, including
our own, are subject to referral bias, but our data suggest
that the prognosis of hypertrophic cardiomyopathy in a
group of elderly patients consisting primarily of outpatients
is favorable. These data contrast with the results of the
majority of prior studies, which have predominantly in-
cluded younger patients. Nonetheless, within the elderly
group, there are those with severe disease, categorized on
the basis of symptoms and echocardiographic features of
increased ventricular septal thickness and left atrial size,
who appear to have an adverse prognosis. This should be
kept in mind in the determination of therapeutic strategies
for elderly patients with hypertrophic cardiomyopathy.
We thank Susan Burns for secretarial assistance and Rick A. Nishimura. MD
for thoughtful review of the manuscript.
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